Epitel Raises $26 Mn to Expand AI-Powered Wireless EEG Monitoring
Advertisement
Epitel's REMI platform combines lightweight, wearable wireless sensors with cloud connectivity to continuously record brain activity over several days or even weeks while patients remain in their normal home environment.
Utah-based digital health startup Epitel has raised $26 Mn in a Series B funding round to expand the availability of its wireless EEG monitoring technology across the United States.
The investment will help the digital health startup strengthen its commercial operations, increase adoption among healthcare providers, and improve access to long-term, AI-supported neurological monitoring for patients with suspected seizures.
The funding round was co-led by Catalyst Health Ventures and Genoa Ventures, with participation from both existing and new investors.
The same venture firms also co-led Epitel's $12.5 Mn Series A financing in 2022, following more than $7.5 Mn in research grants from the U.S. National Institutes of Health and the Epilepsy Foundation.
"Millions of Americans with suspected seizures still face significant barriers to diagnosis because access to EEG remains limited, particularly outside major medical centres," said Steve Pacelli, President & Chief Executive Officer of Epitel.
"Closing this Series B round represents a pivotal milestone for our team. With these resources, we are aggressively building out our commercial footprint to get REMI into the hands of those who will most benefit from it."
Founded in Salt Lake City, Epitel develops AI-enabled neurological monitoring technologies designed to improve access to brain health diagnostics.
Epitel's REMI platform combines lightweight, wearable wireless sensors with cloud connectivity to continuously record brain activity over several days or even weeks while patients remain in their normal home environment.
Its AI-powered software, REMI Vigilenz, assists clinicians by identifying potential seizure events within lengthy EEG recordings, reducing review time while supporting clinical decision-making.
The system has received five FDA 510(k) clearances since its initial authorization in 2021 and is now cleared for neurological monitoring in patients as young as one year old, while its AI-assisted seizure detection supports patients aged six years and older.
Stay tuned for more such updates on Digital Health News
